Englander Institute for Precision Medicine

Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer.

TitleIntraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer.
Publication TypeJournal Article
Year of Publication2025
AuthorsMizuno K, Ku S-Y, Venkadakrishnan VBalaji, Bakht MK, Sigouros M, Chan J, Trigos A, Driskill JH, Manohar J, King A, Presser AG, Kim MJin, Tewari AK, Long HW, Quigley D, Choueiri TK, Balk S, Hill S, Mosquera JMiguel, Einstein D, Sandhu S, Taplin M-E, Beltran H
JournalNat Commun
Volume16
Issue1
Pagination5543
Date Published2025 Jul 01
ISSN2041-1723
KeywordsDNA Methylation, Epigenesis, Genetic, Gene Expression Regulation, Neoplastic, Genetic Heterogeneity, Histones, Humans, Male, Phenotype, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Abstract

Castration-resistant prostate cancer is a heterogeneous disease with variable phenotypes commonly observed in later stages of the disease. These include cases that retain expression of luminal markers and those that lose hormone dependence and acquire neuroendocrine features. While there are distinct transcriptomic and epigenomic differences between castration-resistant adenocarcinoma and neuroendocrine prostate cancer, the extent of overlap and degree of diversity across tumor metastases in individual patients has not been fully characterized. Here we perform combined DNA methylation, RNA-sequencing, H3K27ac, and H3K27me3 profiling across metastatic lesions from patients with CRPC/NEPC. Integrative analyses identify DNA methylation-driven gene links based on location (H3K27ac, H3K27me3, promoters, gene bodies) pointing to mechanisms underlying dysregulation of genes involved in tumor lineage (ASCL1, AR) and therapeutic targets (PSMA, DLL3, STEAP1, B7-H3). Overall, these data highlight how integration of DNA methylation with RNA-sequencing and histone marks can inform intraindividual epigenetic heterogeneity and identify putative mechanisms driving transcriptional reprogramming in castration-resistant prostate cancer.

DOI10.1038/s41467-025-60654-z
Alternate JournalNat Commun
PubMed ID40593552
PubMed Central ID4163115
Grant ListR37CA241486-01A1 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) /
P50 CA272390-0 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) /
HT94252310407 / / U.S. Department of Defense (United States Department of Defense) /
W81XWH-17-1-0653 / / U.S. Department of Defense (United States Department of Defense) /

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021